CONCEPT OF VASCULAR AGE: NEW TOOL IN CARDIOVASCULAR RISK ASSESSMENT
https://doi.org/10.18705/1607-419X-2017-23-2-160-171
Abstract
Increasing interest to the problems of vascular ageing and need in novel parameters reflecting impact of this process on cardiovascular risk have led to the development of a concept of vascular age. Vascular age reflects cardiovascular risk. It is thought to improve cardiovascular risk prediction models and may contribute to a better understanding of cardiovascular risk, especially in young patients. The review summarizes the current knowledge on the definition, assessment and clinical significance of vascular age.
About the Authors
E. A. TroitskayaRussian Federation
PhD, Assistant of the Professor, Department of the Internal Diseases with Cardiology and Functional Diagnostics
S. V. Velmakin
Russian Federation
Assistant of the Professor, Department of the Internal Diseases with Cardiology and Functional Diagnostics
Z. D. Kobalava
Russian Federation
MD, PhD, Professor, Head, Department of the Internal Diseases with Cardiology and Functional Diagnostics
References
1. World Health Organization. http://www.who.int/healthinfo/ global_burden_disease/estimates/en/index1.html (2015)
2. Cuende J. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts. Rev Esp Cardiol. 2016;69(3):243–246. doi: 10.1016/j.rec.2015.10.019
3. Lopez-Gonzalez AA, Aguilo A, Frontera M, Bennasar-Veny M, Campos I, Vicente-Herrero T et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015;22(3):389–96. doi: 10.1177/2047487313518479
4. Łoboz-Rudnicka M, Jaroch J, Bociąga Z, Kruszyńska E, Ciecierzyńska B, Dziuba M et al. Relationship between vascular age and classic cardiovascular risk factors and arterial stiffness. Cardiol J. 2013;20(4):394–401. doi: 10.5603/CJ.2013.0098
5. Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010;1(5):519–23. doi:10.1097/HJR. 0b013e328337ccd3
6. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351–8. doi:10.1093/eurheartj/ehq205
7. Cuende JI, Saltijeral A, Estrada V, Pérez De Isla L. Vascular age calculation and equivalent risk factors in HIV-infected patients obtained from the D: A: D risk equation. Eur J Prev Cardiol. 2016;23(17):1903–1908. doi:10.1177/2047487316663546
8. Карпов Ю. А., Сорокин Е. В. Влияние комбинированной гипотензивной терапии на риск сердечно-сосудистых осложнений и сосудистый возраст: результаты многоцентрового открытого исследования ADVANT’AGE. Атмосфера. Новости кардиологии. 2015;3:18–26. [Karpov YA, Sorokin EV. Effects of combination antihypertensive therapy on the cardiovascular risk and vascular age: the results of ADVANT’AGE — a multi-center open-label study. Atmosphere. News in Cardiology. 2015;3:18–26. In Russian].
9. Groenewegen KA, den Ruijter HM, Pasterkamp G, Polak JF, Bots ML, Peters SA. Vascular age to determine cardiovascular disease risk: A systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol. 2016;23(3):264–74. doi:10. 1177/2047487314566999
10. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315–81. doi:10.1093/eurheartj/ehw106
11. Anderson T, Gregoire J, Pearson G, Barry AR, Couture P, Dawes M et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282. doi:10. 1016/j.cjca.2016.07.510
12. Stein J, Fraizer M, Aeschlimann S, Nelson-Worel J, McBride PE, Douglas PS. Vascular age: integrating carotid intima-media thickness measurements with global coronary risk assessment. Clin Cardiol. 2004;27(7):388–392.
13. D’Agostino RB, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53. doi:10.1161/ CIRCULATIONAHA.107.699579
14. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. For the SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J. 2003;24(11):987–1003.
15. Карпов Ю. А., Сорокин Е. В. Оценка риска осложнений при артериальной гипертонии и сосудистый возраст. Новые инструменты для повышения качества лечения и улучшения взаимопонимания врача и больного. Атмосфера. Новости кардиологии. 2015;2:18–24. [Karpov YA, Sorokin EV. Risk assessment in hypertension and vascular age. New tools for the improvement of the treatment quality and the relationships between the doctor and the patient. Atmosphere. News in Cardiology. 2015;2:18–24. In Russian].
16. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet. 2005;366 (948):895–906. doi:10.1016/S0140–6736(05)67185–1
17. Prieto-Merino D, Dobson J, Gupta AK, Chang CL, Sever PS, Dahlöf B et al. ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J Hum Hypertens. 2013;27(8):492–496. doi:10.1038/jhh.2013.3
18. Кобалава Ж. Д., Котовская Ю. В., Маркова М. А., Алам А., Доронина А. Ю. Сосудистое старение и артериальная гипертония // Кобалава Ж. Д., Котовская Ю. В. Артериальная гипертония в ХХI веке: достижения, проблемы, перспективы. М.: Бионика Медиа, 2015:91–113. [Kobalava ZD, Kotovskaya YV, Markova MA, Alam A, Doronina AY. Vascular ageing and arterial hypertension//Kobalava ZD, Kotovskaya YV. Arterial hypertension in the XXI century: achievements, problems and perspectives. Moscow: Bionica Media, 2015:91–113. In Russian].
19. Котовская Ю. В., Троицкая Е. А., Кобалава Ж. Д. Преждевременное старение сосудистого русла: роль артериальной ригидности и возможности медикаментозной терапии с использованием периндоприла А. Consilium medicum. 2013;15(10):101–107 [Kotovskaya YV, Troitskaya EA, Koba-lava ZD. Early vascular ageing: role of arterial stiffness and treatment options with Perindopril A. Consilium medicum. 2013;15(10):101–107. In Russian].
20. O’Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and micro-vasculature. Vasc Med. 2010;15(6):461–468. doi:10.1177/ 1358863X10382946
21. Nilsson P. Vascular age: how can it be determined? What are it’s clinical applications? Medicographia. 2015;37:454–460.
22. O’Rourke M. Mechanical principles in arterial disease. Hypertension. 1995;26(1):2–9. doi:10.1161/01.HYP.26.1.2
23. Laurent S. Defining vascular aging and cardiovascular risk. J Hypertens 2012;30(Suppl 1):S3-S8. doi:10.1097/HJH. 0b013e328353e501
24. Laurent S, Marais L, Boutouyrie P. The Noninvasive assessment of vascular aging. Can J Cardiol. 2016;32(5):669–79. doi:10.1016/j.cjca.2016.01.039
25. Reece AS, Hulse GK. Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women. Br Med J. 2014;4: e004521. doi:10.1136/bmjopen-2013–004521
26. Takazawa K, Tanaka N, Fujita M, Matsuoka O, Saiki T, Aikawa M et al. Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension. 1998;32(2):365–370.
27. Парфенов А. С. Ранняя диагностика сердечно-сосудистых заболеваний с использованием аппаратно-программного комплекса «Ангиоскан-01». Поликлиника. 2012; 2:1–6. [Parfenov AS. Early diagnostics of cardio-vascular diseases with the new device ANGIOSCAN-01. Polyclinics. 2012;2:1–6. In Russian].
28. de Andrade CR, Silva EL, da Matta MF, Castier MB, Rosa ML, Gomes MB. Vascular or chronological age: which is the better marker to estimate the cardiovascular risk in patients with type 1 diabetes? Acta Diabetol. 2016;53(6):925–933. doi:10. 1007/s00592–016–0891–8
29. McClelland RL, Nasir K, Budoff M, Blumenthal RS, Kronmal RA. Arterial age as a function of coronary artery calcium from the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Cardiol. 2009;103(1):59–63. doi:10.1016/j.amjcard.2008.08.031
30. Bonner C, Jansen J, Newell BR, Irwig L, Glasziou P, Doust J et al. I don’t believe it, but I’d better do something about it: patient experiences of online heart age risk calculators. J Med Internet Res. 2014;16: e120. doi:10.2196/jmir.3190
31. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the check-up study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296–2303. doi:10.1001/archinte.167.21.2296
32. Zacarias A, Vaquero C, Narvaez F, Nolla JM, Gonzalez-Gay MA, Gonzalez-Juanatey et al. Utility of relative cardiovascular risk score scales and vascular age predictors in patients with rheumatoid arthritis UNDER 50 YEARS of age. 2016 ACR/ARHP Annual Meeting Archives: 170, abstract 1464.
33. Clavreul N. Tailored-treatment approach for the management of hypertension. Medicographia. 2015;37:440–448.
34. Asmar RG, London GM, O’Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38(4):922–926.
35. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225. doi:10.1161/ CIRCULATIONAHA.105.595496
36. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.
37. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril andendothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10. 1016/j.cardiores.2006.10.021
Review
For citations:
Troitskaya E.A., Velmakin S.V., Kobalava Z.D. CONCEPT OF VASCULAR AGE: NEW TOOL IN CARDIOVASCULAR RISK ASSESSMENT. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2017;23(2):160-171. (In Russ.) https://doi.org/10.18705/1607-419X-2017-23-2-160-171